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Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IllinoisABSTRACT T-20/Fuzeon/Enfuvirtide (ENF), a peptide inhibitor of HIV-1 infection, targets the grooves created by heptad
repeat 2 (HR2) of Env’s coiled-coil, but mutants resistant to ENF emerge. In this study, ENF-resistant mutants—V38A,
N43D, N43D/S138A, Q40H/L45M—were combined with modified inhibitory peptides to identify what we believe to be novel
ways to improve peptide efficacy. V38A did not substantially reduce infectivity, but was relatively resistant to inhibitory peptides.
N43D was more resistant to inhibitory peptides than wild-type, but infectivity was reduced. The additional mutation S138A
(N43D/S138A) increased infectivity and further reduced peptide inhibitory potency. It is concluded that S138A increased binding
of HR2/ENF into grooves and that S138A compensated for electrostatic repulsion between N43D and HR2. The six-helix bundle
structure indicated that E148A should increase hydrophobic interactions between the coiled-coil and peptide. Importantly, the
modifications S138A and E148A in the same peptide retained potency against ENF-escape mutants. The double mutant’s
increase in potency was greater than the increases from the sum of S138A and E148A individually, showing that these two
altered residues synergistically contributed to peptide binding. Isothermal titration calorimetry established that hydrophobic
substitutions at positions S138 and E148 improved potency of inhibitory peptides against escape mutants by increasing
enthalpic release of energy upon peptide binding.INTRODUCTIONHuman immunodeficiency virus type 1 (HIV-1) is the major
causative agent of the AIDS pandemic. The protein that
mediates fusion of the virus to cells, HIV-1 Env, is a homo-
trimer; each monomer consists of two noncovalently bound
subunits: gp120 and gp41. The fusion subunit, gp41,
contains a six-helix bundle (6HB) that consists of a trimer
of hairpins in its final—but not its initial—state. Before
the formation of the 6HB, gp41 folds into a prehairpin struc-
ture. In this structure, a trimeric coiled-coil (composed of
three heptad repeats, one per monomer, each designated
HR1) has three grooves exposed. During the formation of
this prehairpin, hydrophobic fusion peptides within gp41
become anchored in the target cell membrane. After the pre-
hairpin has formed, three other heptad repeats (HR2) insert
into the three grooves of the coiled-coil to complete the
6HB. Hydrophobic amino-acid residues of HR2 provide
the key interactions with the hydrophobic grooves to form
the stable 6HB (1,2). Steps that lead to bundle formation
drive both formation and enlargement of the fusion pore
(3,4), allowing delivery of the viral core into the cytoplasm
of the target cell, completing the entry process (5). Prevent-
ing bundle formation blocks viral infection.
Synthetic N-peptides that cover some or all of HR1 can be
used to create an experimental model of the natural coiled-
coil. Synthetic peptides that include the amino-acid
sequence of HR2 (such as C34) prevent viral infection by
binding to the grooves of the triple-stranded coiled-coil,Submitted November 27, 2010, and accepted for publication February 28,
2011.
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(1,6). One such peptide, T20/Fuzeon/Enfuvirtide (ENF),
has been clinically approved by the FDA for therapeutic
use against HIV-1 (7). HIV-1 Env rapidly mutates, and it
has been found that the efficacy of ENF treatment for
some patients is reduced over time, due to the accumulation
of HIV-1 mutants that are resistant to the blocking effects of
ENF. This selection of escape mutants can occur quickly,
and these mutants can become prominent after only a few
weeks of ENF therapy (8–10). Analysis of ENF-resistant
isolates shows that the relevant mutations always occur
within residues 36–45 of HR1 (11).
As of this writing, as cited by the International AIDS
Society in 2009, 16 ENF-resistant mutants have been defin-
itively identified (12–18); of those tested, all have a reduced
affinity for ENF; their gp41 mutants still fold into a 6HB,
even in the presence of a high concentration of ENF (19).
The coiled-coils of the mutated trimers should have reduced
affinity for the natural HR2, and in fact, the escape mutants
are less infectious than wild-type (WT) (20). Although the
mechanisms that viruses use to escape inhibitory peptides
are clearly of importance, why these mutations confer
ENF resistance is not molecularly understood. Mutations
could reduce ENF binding for multiple reasons, including
disruption of packing, electrostatic interactions, hydro-
phobic effects, and/or entropic contributions.
The escapemutantN43Dcan become a significant fraction
of the HIV-1 load in patients treated with ENF. Over time,
a second mutation, S138A, can develop on gp41 carrying
N43D. The S138A mutation does not appear unless N43D
is present. The doublemutantN43D/S138Ahas greater resis-
tance to ENF than the single N43D escape mutant (18).doi: 10.1016/j.bpj.2011.02.053
Improved Peptide Potency via Enthalpy 1961Several efforts have been directed toward developing
peptides that retain potency against ENF-escape mutants.
These studies have generally been based on the fact that
ENF is a random coil in solution, but becomes a-helical after
binding to coiled-coils (21). Inhibitory peptides have been
modified by varied means, with the goal of increasing the
a-helicity of inhibitory peptides in solution (22–24), to
reduce the entropic penalty for free energy of binding. In
this study, we have employed an alternate approach. From
inspection of the crystal structure and homology modeling,
wemade changes in an inhibitory peptide that should increase
interactions of the peptide with the grooves of HR1. This
would improve the enthalpic, rather than the entropic, contri-
bution to free energy of binding. We show that a peptide with
two alterations, each of which separately improves interac-
tions, increases inhibitory potency synergistically, and retains
potency against common ENF-escape mutants.EXPERIMENTAL PROCEDURES
Reagents and cells
The X4 HIVHXB2 envelope expression plasmid E7-HXBc2(IIIexE7pA-
Kpn20), which we refer to as pHXB2, was provided by Dr. J. A. Nunberg
(University of Montana, Missoula, MT). HeLa-JC5.3 cells (25) were obtained
from Dr. D. Kabat (OHSU, Portland, Oregon). RPMI-1640 and fetal bovine
serumwere purchased fromHyclone (Logan,UT).AllC-peptideswere synthe-
sized by Genemed Synthesis (San Antonio, TX). Sequences with residues that
were altered from those of C34 are shown in bold and underlined as follows:
C34: WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL.
C-S138A: WMEWDREINNYTSLIHSLIEEAQNQQEKNEQELL.
C-E148A: WMEWDREINNYTSLIHSLIEESQNQQEKNAQELL.
C-S138A/E148A: WMEWDREINNYTSLIHSLIEEAQNQQEKNA
QELL.
C-S138Abu/E148A: WMEWDREINNYTSLIHSLIEEAbuQNQQEKNA
QELL.
N36 and N46 have the amino-acid sequences:
N36: .......SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQL
QARIL.
N46: .......TLTVQARQLLSGIVQQQNNLLRAIEAQQHLL
QLTVWGIKQLQARIL.Homology models for the structure of the 6-helix
bundle of gp41 mutants resistant to ENF
Homologymodels were generated using the Swiss-PDB-viewer. The structure
for the S138Amutation was generated by using the crystal structure of HIV-1
gp41 6HB (pdb:1F23) as a template. Using the NMR structure of the 6HB of
SIV gp41 (pdb:2EZO) as a template yielded the same result. Residue E148 is
not part of 1F23, but is included in 2EZO, and so the structure for E148Awas
generated by using 2EZO as a template. The final homology model for a
mutated residue was generated by energy minimization which was executed
for all atoms. The side chains of amino acids are displayed in figures as either
stick or van derWaals structures. In figures, atoms are colored according to the
Corey/Pauling/Koltun scheme: N is blue, O is red, C is white, and S is yellow.Site-directed mutagenesis
The pHXB2 plasmid was used to express HIV Env (HXB2 requires CXCR4
for infection). A double PCR method was used to generate mutants of thisenvelope protein. In the first round of PCR, forward and reverse primers
(2 mg of each) were added to 96 mL of a PCR cocktail containing 250 ng
of plasmid DNA, 3 units of Pfu DNA polymerase, and 1 unit of Taq2000
DNA polymerase (Stratagene, La Jolla, CA). The forward primer carried
the NheI site with the sequence derived from 1610-1636 of pHXB2; the
reverse primer contained the mutated codon and had ~40 nucleotides flank-
ing both sides of the codon. The product of first round of PCR was used as
the forward primer in the second round of PCR. The reverse primer for the
second PCR carried the BamHI site with a sequence derived from 2810-
2838 of pHXB2. The first PCR consisted of 33 cycles of denaturing at
95C for 30 s, annealing at 55C for 30 s, and extending at 72C for
3 min. The second PCR used the same cycling protocol, but with a 4 min
extension time. The PCR product containing the mutant codon was ligated
into the NheI and BamHI sites of pHXB2.Generation of HIV/HIV pseudotyped virus
The day before transfection, HEK293T cells were seeded, in 6 cm2 dishes,
at 5.5  105 cells in 5 mL of RPMI-1640 culture medium supplemented
with 10% fetal bovine serum. For transfection, 15 mg each of pHXB2
and pNL4-3.Luc.R-E- (National Institutes of Health AIDS Research and
Reference Reagent Program, Bethesda, MD) were added to the
HEK293T cells by a standard calcium phosphate method. The culture
supernatant contained pseudotyped viruses; it was collected two days after
transfection and passed through a 0.45 mm filter.Infectivity assay
A collected supernatant (320 mL) that contained virions was added to 50 mL
of RPMI-1640 þ 10% FCS bathing 2  105 HeLa-JC5.3 cells/mL (25)
within a well of a multi-well plate (CulturPlate 96; Perkin Elmer, Wellesley,
MA). The virus-cell mixture was cultured for two days before performing
a luciferase assay (Promega, Madison, WI). The luciferase reading was
normalized by the p24 level in the virus-containing medium. The level of
p24 was determined by ELISA (Perkin Elmer).Isothermal titration calorimetry
We performed isothermal titration calorimetry (ITC) measurements with
a high-sensitivity VP-ITC instrument (MicroCal, Northampton, MA).
Peptides were dissolved in 50 mM NaHPO4 and 50 mM NaCl. We titrated
the solution to pH 8.0 because C-S138A/E148A was not soluble at pH 7.4
and lower. All solutions were degassed under vacuum just before use.
Multiple injections of 150 mM of C34 or C-S138A/E148A were delivered
into a reaction cell, maintained at 25C, containing 5 mM N46 (26). The
solution was stirred at 300 rpm; the time between injections was 5 min.
The heats of dilution were determined by injecting C34 or C-S138A/
E148A into the sodium phosphate buffer in the absence of N46. The ther-
modynamic parameters characterizing binding of C34 or C-S138A/E148A
to N46 were determined with the MicroCal Origin software (Ver. 7.0), using
a model that assumes that an N46 trimer contains three independent binding
sites for a C-peptide.RESULTS
Rationale
We utilized the crystal structure of the 6HB of WT HIV-1
Env as a template to investigate how the escape mutations
alter the bundle (pdb:1F23). In the three-dimensional struc-
ture, WT residue N43 of HR1 is physically closer to E137
than to S138 of HR2. Because the electrically neutralBiophysical Journal 100(8) 1960–1968
1962 Leung and Cohenasparagine (N43) and the negatively charged aspartic acid
(N43D) are virtually the same size, differing by only one
hydrogen atom, the mutation N43D should not alter the
packing of the 6HB for geometrical reasons. Rather, the
mutation N43D should reduce the adhesion between HR1
and HR2 (or ENF) because N43D should electrostatically
repel residue E137.
Previous investigators inspected a single monomer within
the trimeric crystal structure of the 6HB of HIV-1 Env and
concluded that the S138 side chain interacts with Q40
and L45 (18). We examined the crystal structure while
viewing the full trimer and found that S138 fits into a hydro-
phobic pocket formed by N43, L44, L45, A46, and I48 of
HR1 (Fig. 1 A shows the pocket, Fig. 1 B illustrates the posi-
tion of S138 within the pocket, and Fig. 1 C shows that the
mutation S138A is well positioned within the pocket). Q40
is not part of the pocket and is separated from S138 by
~1.3 nm. Thus, Q40 should not significantly interact with
S138, contrary to prior conclusions drawn by others. Identi-
fication of the hydrophobic pocket is critical for under-
standing how S138 interacts with the grooves created by
HR1 (27). Based on size and shape, Ala should fit into the
hydrophobic pocket as well as Ser does, and so the substitu-
tion of Ala for Ser at position 138 should increase the adhe-
sion between HR1 and HR2. That is, the naturally occurring
S138 may not be optimal for binding into grooves. By this
line of reasoning, the second mutation S138A (yielding
N43D/S138A) is favorable for infection in the presence of
ENF because the greater hydrophobicity of alanine at posi-
tion 138 aids hydrophobic interactions between HR1 and
HR2 (Fig. 1 D, left, shows WT and right shows N43D).
The NMR structure of SIV gp41 covers a longer stretch
than the crystal structures of HIV-1 gp41, so we used theBiophysical Journal 100(8) 1960–1968NMR structure (2EZO) of the 6HB to locate unidentified
positions where changes in an HR2 peptide could improve
inhibitory potency. We found that E148 is in close proximity
to L33 and S35 (Fig. 2). Since completing this study,
a crystal structure covering the NMR structure has been
published (28). The two structures are quite similar, and
our interpretations are consistent with both. So an inhibitory
peptide containing E148A should have a more favored
hydrophobic interaction with L33 and less electrostatic
repulsion with S35, thereby increasing the peptide’s potency
against infection.Effect of mutation on viral infectivity
We created several pseudotyped viruses that carried known
ENF-resistant mutations and determined their levels of
infectivity (Fig. 3) and of inhibition by C34. We used C34
as our test peptide, rather than ENF, because C34 is easier
and less costly to synthesize (21); more reversibly binds to
the grooves of the trimeric coiled-coil; shows much less
nonspecific binding to surfaces (4); and is more potent in
blocking infection and fusion (29). Although C34 is not
useful for clinical purposes because it is quickly cleared
by the body (30), C34 is superior to ENF for basic experi-
mental studies.
The naturally occurring escape mutant V38Awas almost
as infectious as WT (Fig. 3), as reported by others
(29,31,32), and C34 was approximately four-times less
potent against this mutant than against WT (Fig. 4, Table 1).
The escape mutant N43D exhibited low infectivity (Fig. 3),
probably because of greater electrostatic repulsion of HR2.
We found that N43D is more resistant against C34 (Fig. 4,
Table 1). Our introduction of a second mutation to createFIGURE 1 Protein homology models of the
6HB for the mutations S138A and N43D. (A)
The hydrophobic pocket—formed by N43, L44,
L45, A46 and I48—that interacts with S138 and
S138A, is shown within the molecular surface of
a HR1 trimer. HR2 is shown as a green helix. (B)
The positioning of S138 (the serine side chain is
yellow) within the pocket is shown. (C) The
alanine side chain (shown in orange) for the muta-
tion fits well into the pocket. (D) The consequences
of the mutation N43D on the structure of the 6HB.
This panel is divided into two parts; the left shows
WT and the right shows N43D. N43 and N43D are
in close apposition to E137. The mutation N43D
only changes the side chain by one Dalton, so
size changes are irrelevant. But the net negative
charge introduces a electrostatic repulsion between
N43 and E137 which should reduce the affinity of
HR1 for HR2/ENF. (Yellow) HR1 helices. (Green)
HR2 helices.
FIGURE 2 The consequences of the mutation E148A on the 6HB struc-
ture. (Left) WT. (Right) Mutant. E148 abuts L33 and is close to S35. The E
to A substitution should improve the hydrophobic interaction with L33 and
reduce electrostatic repulsion with S35.
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FIGURE 4 Inhibitory potency of C34 against virions pseudotyped with
Env proteins that are escape mutants against ENF.
Improved Peptide Potency via Enthalpy 1963N43D/S138A increased infectivity by almost 100% (Fig. 3).
It also reduced the potency of C34 bymore than a factor of 10
as compared to WT and a factor of five compared to N43D
(Fig. 4). Introducing the S138A mutation alone did not
greatly affect infectivity. We found that the mutant E148A
was somewhat less infectious than WT.Interactions between HR1 and HR2 are
not optimal in WT
Because Env undergoes large-scale conformational changes
during membrane fusion, an altered HR2 could modify
many steps, in addition to HR2 packing, in fusion and viral
infectivity, and it would not be possible to pinpoint all theseFIGURE 3 Extents of viral infectivity for ENF escape mutants. Infec-
tivity was normalized by the p24 level for that mutant. The means were
determined from the averages of three separate experiments. Error bars
are mean5 SE.interactions. Altered peptides, however, provide a focused,
specific way to study packing into grooves. To explore adhe-
sions between HR1 and HR2 in bundle formation, peptides
with the sequence of C34 were synthesized, but with an
alanine placed at selected positions.
We used a C34 analog corresponding to S138A (position
22 of C34) which we denote as C-S138A; an analog corre-
sponding to E148A (denoted C-E148A); and an analog cor-
responding to mutations at both positions (C-S138A/
E148A). We found that there were only small variations in
the potency of these peptides in inhibiting infection by
WT (Fig. 5 A, Table 1). Within this range, C-S138A/
E148A was the most potent of the four peptides. To further
differentiate the potency of the inhibitory peptides, we
tested them against several mutant pseudovirions (Table 1):
V38A (Fig. 5 B), N43D (Fig. 5 C), and N43D/S138A
(Fig. 5 D).
It is striking that for all the mutant pseudovirions, the
potency of the peptides always followed the same sequence:
C-S138A/E148A > C-S138A > C-E148A > C34. We also
compared the potency of C-S138A/E148A and C34 against
the double mutant pseudovirus Q40H/L45M. Here too,
C-S138A/E148A was dramatically more potent that C34
(Table 1). It is clear that the alteration S138A or E148A in
C34 significantly enhanced inhibitory potency of theTABLE 1 Antiviral activity of C34 modified peptides against
HIV-1 ENF resistant mutants
Pseudotyped
virus
IC50 (nM)
C34 C-E148A C-S138A
C-S138A/
E148A
C-S138Abu/
E148A
WT 40 (1) 35 (1.1) 41 (1) 32 (1.3) 29 (1.4)
V38A 155 (1) 110 (1.4) 57 (2.7) 23 (6.7) /
N43D 77 (1) 78 (1) 30 (2.6) 11 (7) 8 (9.6)
N43D/S138A 408 (1) 331 (1.2) 140 (2.9) 37 (11) 26.5 (15.4)
Q40H/L45M >6000 (1) / / 199 (>30) /
Viral infectivity was determined with a luciferase assay. The ratio of the
IC50 of C34 relative to each modified peptide is shown in parentheses.
The value of IC50 for C-S138Abu/E148A against V38A was not deter-
mined. WT, wild-type.
Biophysical Journal 100(8) 1960–1968
FIGURE 5 The inhibitory potency of pseudotyped viruses against C34 and analogs. (A) WT Env, (B) V38A Env, (C) N43D Env, and (D) N43D/S138A
Env. The doubly mutated peptide was the most potent inhibitory peptide for all viruses tested; C34 was the least potent.
1964 Leung and Cohenpeptides against ENF-escape mutants. The decrease in
IC50 of C-S138A/E148A compared to that for both
C-S138A and C-E148A is much greater than that expected
for additive effects, strongly indicating that packing of
S138 and E148 into grooves is synergistic, rather than
independent.
Because the improvement in peptide efficacy at position
S138 should be due to the greater hydrophobicity of Ala
as compared to Ser, we switched position 138 of C34 to
the synthetic amino acid, a-aminobutyric acid (Abu). Abu
has an ethyl side chain that is more hydrophobic than the hy-
droxylmethyl side chain of Ser and is comparable in size
(albeit slightly larger) (Fig. 6 A). We compared the potency
of the peptide which has S138Abu and E148A (C-S138Abu/
E148A) against C-S138A/E148A as well as the other altered
peptides. C-S138Abu/E148A displayed the highest inhibi-
tory potency against both N43D (Fig. 6 B) and N43D/
S138A (Fig. 6 C), the two mutated pseudovirions that we
tested (Table 1). The greater hydrophobicity of the ethyl
side chain was sufficient to make C-S138Abu/E148A
approximately one-order-of-magnitude more potent against
the N43D pseudovirion than C34. But C-S138Abu/E148A
was only somewhat more potent than C-S138A/E148A. The
greater relative potency of C-S138Abu/E148A compared toBiophysical Journal 100(8) 1960–1968the other two peptides was more pronounced for the N43D/
S138A pseudovirion (Table 1).Helicity of peptides and stability of the bundle
C34 is unstructured in solution, but becomes a-helical upon
binding to a groove of the triple-stranded coiled-coil ((33),
Lu). Ala favors the formation of a-helices (34), so
improved inhibitory potency of the S138A and E148A
modifications (separately or together) in the peptide may
not have occurred through promotion of more favorable
interactions with the grooves of HR1, but rather because
of an increase in helicity of the peptide in solution.
Measuring the CD spectra of the peptides, we found that
they all have similar helical content in solution: between
3% and 4% (see Fig. S1 in the Supporting Material). In
fact, the helicity of C34 is somewhat higher than that of
the modified peptides, even though the modified peptides
are the more potent. The invariance of helicity shows the
modifications did not change the configurational order of
the peptide. But other configurations, such as waters of
hydration, could be altered.
A greater affinity of an HR2 peptide for the coiled-coil
created by HR1 peptides would yield higher bundle stability.
FIGURE 6 Inhibition of infection by C34 and
modified peptides for virus pseudotyped with
N43D and N43D/S138A. (A) The methyl side
chain of alanine, the hydroxylmethyl side chain
of serine, and the ethyl side chain of a-aminobuty-
ric acid are shown. The size and shape of an ethyl
side chain closely resemble that of hydroxyl-
methyl, but it is more hydrophobic. (B) Inhibition
curves of peptides against N43D pseudotyped
virus. (C) Inhibition curves for N43D/S138A. Re-
placing serine by the more hydrophobic a-amino-
butyric acid increased peptide potency.
Improved Peptide Potency via Enthalpy 1965Wemeasured thermal unfolding transition/melting tempera-
tures (Tm values) of bundles formed by HR1 and HR2
peptides to assess bundle stability. We used N36 as the
HR1 peptide, used WT and our modified C34 peptides as
the HR2 peptides, and measured Tm for the resulting
6HBs. This yielded measurable values of Tm without the
need to add denaturants (e.g., guanidinium chloride). (In
contrast, using N46 and C34 led to a 6HB that could not
be melted without adding a denaturant.) The order of the
values of Tm was the same as the general order for potency
of inhibition by the peptides for viral infection: C-S138Abu/
E148A > C-S138A/E148A > C-S138A> C-E148A > C34
(Table 2). However, for virions with mutations correspond-
ing to these peptide positions, infectivity did not follow this
pattern (Fig. 3). Because inhibitory peptides should be
specific in blocking bundle formation, their order of inhibi-
tion should be a reasonably direct measure of effect of muta-
tion on bundle formation.TABLE 2 Thermal unfolding transition temperature (Tm)
of 6HB complexes between N36 and variants of C34
Six-helix bundle complex Tm (
C)
N36, C34 39
N36, C-E148A 41
N36, C-S138A 46
N36, C-S138A/E148A 48
N36, C-S138Abu/E148A 49Enthalpic and entropic contributions to the free
energy of binding
We performed ITC measurements to determine the change
in enthalpy upon peptide binding and to calculate the corre-
sponding changes in free energy and entropy. We compared
binding of WT C34 and C-S138A/E148A to N46 because
these two C-peptides showed the greatest difference in
potency of inhibiting infection. As is obvious from the
raw data (Fig. 7, upper panels), binding of the double
mutant reaches equilibrium at much lower concentrations
than binding of C34. This is reflected in the binding curves
(Fig. 7, lower panels). Quantitatively, the binding affinity is
significantly greater for the double mutant: under our condi-
tions, the association constant K is 4.5  106 M1 for the
double mutant and only 6  105 M1 for C34 (Table 3).
The change in enthalpy of binding was appreciably different
for the two peptides, 5.2 kcal/mol more favorable for C-
S138A/E148A. This was partially compensated by
a 3.5 kcal/mol more favorable entropic contribution to
binding for C34. In conclusion, C-S138A/E148A is
a more potent inhibitory peptide than C34 because it binds
more avidly to the grooves of HR1 than does C34, and
does so because it has a greater enthalpic release of energy
upon binding.
The entropy change upon binding was less favorable for
C-S138A/E148A than for C34. It has been found by others
that even much larger changes in entropy of binding of C34
occur for single alterations of the N-peptide, N36 (26).Biophysical Journal 100(8) 1960–1968
FIGURE 7 ITC measurements of C34 (left) and
C-S138A/E148A (right) binding to N46. (Upper
panels) Raw thermographs. (Lower panels) Fitted
binding isotherms. The ordinates of the upper
panels are the heat flows (power) resulting from
each injection; the ordinates of the lower panels
are the integrated areas over time of each spike of
the corresponding upper panel, yielding the heat
(enthalpy) exchanged after each injection. The
abscissas of the lower panels are the molar ratios
of the indicated C-peptide/ N46. A quantity of
5 mM N46 was initially added to the cuvette. The
DG of C-S138A/E148A binding is ~1 kcal mol1
more negative than that of C34 binding, and is
almost entirely enthalpy-driven. DH (see Table 3)
contributes ~90% of the DG for C-138A/E148A,
but only 44% of DG for C34. Note that the scales
are different for C34 and C-S138A/E148A.
1966 Leung and CohenPossible molecular reasons for the less favorable entropic
contribution for S138A/E148A include the reduced number
of carbon bonds for rotation in the altered side chains
(particularly for Ala as compared to Glu), less freedom of
the mutated peptide once it is bound to grooves of the
coiled-coil (because Ala fits better into the grooves than
the natural amino acids), and altered configurations of water
surrounding unbound peptides caused by hydrophobic
alanines.DISCUSSION
The order for the potency of the peptides in preventing viral
infection and the stability of the bundles (as measured by
Tm) they form with an HR1 peptide (N36) followed the
same sequence: C-S138Abu/E148A > C-S138A/E148A >
C-S138A > C-E148A > C34. Although bundle stability
does not correlate with either extents or kinetics of fusion
(35–37), we have now found that stability does correlate
with the ability of a peptide to inhibit fusion. We consider
it notable that the order of inhibition by the peptides we
used is accounted for by the interactions inferred from the
crystal structure (see Rationale, above). It has recently
been shown that the qualitative order of inhibitory potency
for a set of ENF analogs also follows alterations in interac-TABLE 3 Thermodynamic parameters of C34 and C-S138A/
E148A binding to N46
DH
(kcal mol1)
TDS
(kcal mol1)
DG
(kcal mol1) K (M1)
C34 3.5 4.4 7.9 6.6  105
C-S138A/E148A 8.2 0.9 9.1 4.5  106
Biophysical Journal 100(8) 1960–1968tions that were deduced, by the same logic we employed,
from the crystal structure (31).The appearance of escape mutants
The mutation V38A is frequently found in patients under-
going ENF treatment. This is undoubtedly related to the
decreased potency of ENF against this mutant (19) and
the fact that the mutant virus retains>80% of the infectivity
of WT (Fig. 3). The propagation advantage of N43D should
rest on its increased resistance to ENF over WT (38). We
infer from the crystal structure that the mutated N43D virus
is electrostatically repelled from E137, and this could
account for its reduced infectivity. The compensatory muta-
tion S138A that appears after N43D is selected (i.e., N43D/
S138A) in the presence of ENF partially restores infectivity,
but it is still far short of the infectivity of WT. The greater
hydrophobic interactions between S138A and the hydro-
phobic pocket, leading to the greater infectivity of the
double than the single mutant, should partially—but not
completely—offset the increased electrostatic repulsion
arising from N43D. The combination of increased infec-
tivity and greater resistance to an inhibitory peptide is prob-
ably the reason the mutation S138A arises, during ENF
treatment of patients, after the first mutation N43D appears.
Inspection of the bundle’s crystal structure indicated that
changing E148 to alanine would improve the inhibitory effi-
cacy of the peptide because of the reduction in charge and
the increase in hydrophobicity. Reduced infectivity of
E148A, despite these more favored interactions, indicates
that mutations of residues in the bundle region affects
processes other than formation of the bundle itself—perhaps
including viral assembly, protein folding, conformations of
Improved Peptide Potency via Enthalpy 1967intermediates, or compatibility with other domains of gp41.
C-E148A was somewhat more effective than C34 in block-
ing fusion. C-S138A/E148A, on the other hand, was consid-
erably more potent than C34, C-S138A, or C-E148A in
blocking infection by WT and the viral mutants. It might
thus be thought that this double mutation would appear in
the presence of ENF. However, this has not been reported,
and BLAST software did not show protein sequences con-
taining S138A and E148A in HIV-1 Env.
The modified C34 peptides had varied potencies against
all the mutant virions, but all the peptides had the same
inhibitory activity against WT virus. For a peptide to inhibit
fusion, it must bind to prehairpin structures of gp41. This
can only occur while the virions are still bound to the plasma
membrane, before their endocytic internalization (5,39). It is
possible that WT virus is internalized faster than the
mutants, and binding of the peptides is limited by this
internalization.Thermodynamic reasons for improved peptide
potency
Unbound inhibitory peptides reconfigure from a less ordered
to a more ordered structure upon associating with HR1.
Greater order leads to a decrease in entropy, and because
this is energetically unfavorable, it must be compensated
by a greater favorable decrease in enthalpy if the peptide
is to bind (40,41). Investigators have introduced covalent
constraints (42) or intramolecular salt bridges (23,24,42)
to increase ENF helicity in solution. These modifications
increased the inhibitory potency of the peptides, demon-
strating that reducing the entropic penalties of binding
improves efficacy of the peptides. Our modifications, on
the other hand, did not affect helicity of the peptides in solu-
tion (Fig. 7), and so increased potencies of the peptides
would likely be caused by more favorable enthalpic contri-
butions to binding. The results of our ITC experiments
confirm this expectation. A more favored enthalpy is equiv-
alent to increased adhesive forces between the modified
peptides and HR1 grooves. Based on the crystal structure,
more favorable hydrophobic interactions with the HR1
grooves are responsible for the greater adhesive forces (27).
For bundle stability to directly vary with the strength of
hydrophobic interactions between HR1 and a peptide, the
substitutions should not disfavor geometrical packing of
the peptide into the grooves. For C-S138A, Ala’s methyl
side chain is smaller than the hydroxylmethyl side chain
of Ser. Visual inspection of the crystal structure indicates
that alanine’s methyl group fits very well into the hydro-
phobic pocket formed by N43, L44, L45, A46, and I48 of
HR1 (Fig. 1), possibly better than the hydroxylmethyl side
chain serine that normally occupies it. C-E148A should
more favorably pack into HR1 grooves than does C34
because it should have a more favorable hydrophobic inter-action with L33 than does C34 without causing any geomet-
rical clashes.
The synergistic increase in inhibitory potency of
the doubly changed peptides C-S138A/E148A and
C-S138Abu/S148A is likely to be a consequence of the
two hydrophobic patches created by the substitutions. The
distance between the centers of these two patches, separated
by three a-helical turns, should be ~1.6–1.7 nm. Therefore,
a linear chain of approximately six water molecules sepa-
rates the two hydrophobic patches. The network of H-bonds
between water molecules adjacent to a hydrophobic patch
will be altered (43), so much (or all) of the H-bond network
between the patches should be different from that of bulk
water. We propose that the altered H-bond structure inter-
vening between the patches reduces the energy necessary
to remove the water molecules separating HR2 from the
grooves created by HR1, and this is the direct mechanistic
cause of the synergic greater binding.
In this study we have shown that the potency of inhibitory
peptides can be improved by designing them to yield greater
enthalpic release of energy upon binding. It should be
possible to design inhibitory peptides that yield both more
favorable entropic and enthalpic contributions to free energy
release upon peptide binding to coiled-coils of viral fusion
proteins, thus maximizing the potency of peptides in preven-
tion of infection. Our proposed physical principle that
nearby hydrophobic patches synergistically improves
peptide binding may prove to be a useful and general prin-
ciple for design of inhibitory peptides to maximize enthalpic
energy release upon binding to hydrophobic grooves of
coiled-coils. In any case, our finding that the joint alterations
S138A and E148A in C34 yield a peptide that retains full
inhibitory potency against the tested escape mutants could
provide the basis for a second generation of inhibitory
peptides, ones that retard the appearance of a large number
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